Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 53.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,954 shares of the life sciences company’s stock after selling 24,149 shares during the quarter. Amalgamated Bank’s holdings in Integra LifeSciences were worth $611,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Blue Trust Inc. raised its holdings in shares of Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC lifted its holdings in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares during the period. Valley National Advisers Inc. purchased a new stake in shares of Integra LifeSciences in the first quarter worth about $63,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after buying an additional 1,711 shares during the last quarter. Finally, Northwest Investment Counselors LLC acquired a new stake in Integra LifeSciences during the first quarter worth about $143,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Up 2.3 %

IART stock opened at $17.87 on Friday. The stock has a market capitalization of $1.39 billion, a P/E ratio of 35.74, a P/E/G ratio of 0.60 and a beta of 1.10. Integra LifeSciences Holdings Co. has a 52 week low of $16.96 and a 52 week high of $45.42. The firm has a 50-day simple moving average of $21.33 and a 200-day simple moving average of $27.20. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.62 by $0.01. The firm had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.71 earnings per share. Equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IART. Citigroup decreased their price target on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating for the company in a report on Thursday, August 22nd. Morgan Stanley increased their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. BTIG Research cut their price objective on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a report on Wednesday, August 28th. JMP Securities decreased their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Finally, Truist Financial dropped their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.